Welcome to our dedicated page for Quoin Pharmaceuticals, Ltd. news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals, Ltd. stock.
Quoin Pharmaceuticals Ltd. (symbol: QNRX) is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing therapeutic products for rare and orphan diseases. Founded with a commitment to addressing unmet medical needs, Quoin focuses on innovating treatments that can make a significant impact on patients’ lives.
Quoin’s research and development pipeline includes potential treatments for a range of conditions such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and Epidermolysis Bullosa. Their work is particularly focused on Netherton Syndrome, a rare genetic disorder characterized by defective skin barrier function.
Recently, Quoin made significant strides in its clinical studies for Netherton Syndrome. Protocol amendments, based on initial positive data, were approved by the FDA and include increasing study sizes, modifying dosing frequencies, and broadening eligibility criteria. These changes aim to enhance the potential for a successful outcome.
Furthermore, Quoin expanded its intellectual property portfolio by filing both US and international patent applications for a novel combination product to treat Netherton Syndrome. They are also exploring additional patent opportunities related to the clinical and manufacturing aspects of their products.
Financially, Quoin has strengthened its position through a successful public offering and the execution of an equity line of credit arrangement, extending their cash runway into late 2025. This financial stability supports the company as it pursues key milestones in its development pipeline.
Under the leadership of Dr. Michael Myers, Quoin Pharmaceuticals is poised to make significant advancements in the field of rare and orphan disease treatments. The company continues to engage with the investment community and stakeholders through various communication channels, ensuring transparency and building investor confidence.
To stay updated on Quoin Pharmaceuticals' latest developments, visit their website or follow them on LinkedIn.
Quoin Pharmaceuticals (NASDAQ: QNRX) announces the international expansion of its clinical trials for Netherton Syndrome. The first international site will open at a research hospital in Saudi Arabia, which is currently treating eligible Netherton patients. An experienced local Clinical Research Organization will manage the study. The site will operate under Quoin's IND application with the US FDA. Additional international sites are also being planned. CEO Dr. Michael Myers highlighted that this expansion aims to accelerate patient recruitment and diversify the patient population. Quoin is conducting two ongoing trials evaluating QRX003, a topical lotion, for Netherton Syndrome.
Quoin Pharmaceuticals (NASDAQ: QNRX) announced its sponsorship of the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference in Albuquerque, NM, from June 28-30, 2024. As a Bronze Sponsor, Quoin will support this biennial event aimed at educating and connecting individuals affected by ichthyosis and other skin disorders. Quoin's COO, Denise Carter, emphasized the company's commitment to raising awareness and developing treatments for rare diseases, including their ongoing clinical trials for QRX003, a topical lotion targeting Netherton Syndrome. The company will also sponsor the conference's celebration dinner on June 29, 2024.
Quoin Pharmaceuticals (NASDAQ: QNRX) has signed a research agreement with University College Cork (UCC) to develop novel topical formulations of Rapamycin (sirolimus) targeting rare and orphan diseases. The focus is on using UCC's proprietary dissolvable microneedle technology to enhance local drug delivery and therapeutic effectiveness. This research program, funded by Quoin, aims to create innovative treatments for diseases lacking approved therapies. Quoin will have the option to advance clinical development without paying upfront fees or royalties. UCC's microneedles dissolve upon skin penetration, offering advantages like painless administration and minimal trauma.
Quoin Pharmaceuticals, a specialty pharmaceutical company, announced positive clinical developments in Netherton Syndrome, including FDA clearance for teen recruitment and protocol amendments for ongoing studies. The company extended its cash runway into late 2025 and expanded its patent portfolio. Financially, Quoin had $14.7 million in cash, with a net loss of $2.3 million for the first quarter of 2024.
Quoin Pharmaceuticals (QNRX) will reveal its first quarter 2024 financial results on May 9th, 2024. The announcement will cover operational progress and financial highlights.
FAQ
What is Quoin Pharmaceuticals?
What diseases is Quoin Pharmaceuticals targeting?
What are the recent achievements of Quoin Pharmaceuticals?
Who is leading Quoin Pharmaceuticals?
How can I stay updated on Quoin Pharmaceuticals' news?
What is Netherton Syndrome?
What financial strategies has Quoin Pharmaceuticals implemented recently?
What is unique about Quoin Pharmaceuticals' approach?
Are Quoin Pharmaceuticals' statements forward-looking?
Where is Quoin Pharmaceuticals listed?
